RSV prophylaxis for high-risk infants is achieved with which monoclonal antibody?

RSV prophylaxis for high-risk infants is achieved with which monoclonal antibody?

• A. Rituximab
• B. Palivizumab
• C. Trastuzumab
• D. Bevacizumab

Answer: (B)

RSV prophylaxis in high‑risk infants is achieved with a monoclonal antibody that provides passive protection by directly neutralizing RSV. This antibody targets the virus’s fusion (F) protein, blocking entry into cells and reducing the risk of hospitalization from RSV bronchiolitis. It is given as monthly injections during the RSV season to infants who are most at risk, such as those who are very preterm or have certain heart or lung conditions. The other monoclonal antibodies listed are used for different diseases (for example, targeting CD20, HER2, or VEGF) and are not used for RSV prevention.

RSV prophylaxis in high‑risk infants is achieved with a monoclonal antibody that provides passive protection by directly neutralizing RSV. This antibody targets the virus’s fusion (F) protein, blocking entry into cells and reducing the risk of hospitalization from RSV bronchiolitis. It is given as monthly injections during the RSV season to infants who are most at risk, such as those who are very preterm or have certain heart or lung conditions. The other monoclonal antibodies listed are used for different diseases (for example, targeting CD20, HER2, or VEGF) and are not used for RSV prevention.